#sarilumab

[medicomunicare]

Sarilumab vs. polymyalgia rheumatica: it's time to kill that alive and kickin' pain

Polymyalgia rheumatica (PMR) is characterized by pain and morning stiffness in the shoulder and hips and affects people over the age of 50. It can significantly affect quality of life, and currently is mainly treated with the steroid, glucocorticoids. Although glucocorticoids can control the condition, more than half of PMR patients suffer relapse of their condition when reducing their steroid…

[datastringconsulting]

Rheumatology Revolution: Sarilumab’s $1.1218 B Surge on the Horizon

Sarilumab—the monoclonal antibody that once played second fiddle—is stepping into the limelight, with the global Sarilumab market projected to hit $1.1218 billion by 2035. As physicians demand targeted, high‑efficacy solutions for rheumatoid arthritis and other autoimmune disorders, Sarilumab’s IL‑6 receptor blockade is carving out a premium niche in an increasingly crowded biologics arena.

Breaking New Ground in Autoimmunity

Originally approved for moderate‑to‑severe rheumatoid arthritis, Sarilumab’s next act is expansion into giant cell arteritis, juvenile idiopathic arthritis, and even off‑label trials for cytokine storm syndromes. Its once‑monthly subcutaneous dosing contrasts with bi‑weekly regimens of legacy TNF‑inhibitors, delivering patient‑centric convenience without sacrificing disease control. Real‑world data is stacking up: patients switched from tocilizumab report similar ACR50 response rates but cite fewer injection‑site reactions and improved quality‑of‑life scores.

Market Dynamics & Competitive Edge

Premium Positioning: Despite biosimilar pressure on other biologics, Sarilumab’s patent protection through 2032 buys R&D teams breathing room to refine delivery devices—think auto‑injectors with real‑time dosage feedback.

Payer Partnerships: Value‑based contracting pilots in Europe and the U.S. tie reimbursement to sustained remission rates, aligning payer priorities with patient outcomes and locking in formulary access.

Emerging Regions: Latin America and Asia‑Pacific are growth catalysts. Brazil’s Ministry of Health added Sarilumab to its rheumatoid arthritis protocol in 2029, and China’s National Medical Products Administration granted accelerated review for pediatric indications this year.

Innovation Pipeline & Formulation Advances

Biotech labs aren’t resting on their laurels. Next‑gen Sarilumab variants with half‑life extensions and dual‑mechanism fusions (combining IL‑6R blockade with T‑cell modulation) are in preclinical stages. Lyophilized, room‑temperature stable syringes are slated for launch in 2028, slashing cold‑chain costs and boosting accessibility in resource‑limited settings. Meanwhile, inhalable microsphere formulations—still a moonshot—promise direct lung delivery for COVID‑19–related cytokine storms.

Challenges on the Horizon

No blockbuster sails unchallenged.

Biosimilar Encroachment: As patents begin to expire in certain markets by the early 2030s, Sarilumab must lean into device patents and proprietary auto‑injector designs to maintain premium pricing.

Safety & Long‑Term Data: IL‑6 blockade carries infection and lipid‑profile risks. Ongoing pharmacovigilance studies and real‑world registries will determine whether Sarilumab’s safety profile holds over decades of use.

Market Saturation: With multiple IL‑6 inhibitors and JAK‑inhibitors vying for share, Sarilumab’s brand must stay on point—think high‑touch patient support, digital disease‑management apps, and HCP educational symposia.

The Road Ahead

By 2035, success won’t just be hitting $1.1218 billion—it’ll be about securing Sarilumab’s place as the go‑to IL‑6 agent across indications. Companies that pair clinical innovation with patient‑first delivery systems, data‑driven payer value propositions, and razor‑sharp market access strategies will own rheumatoid arthritis treatment—and beyond.

Source: DataStringConsulting

[delightfulearthquakeparadise]

Innovative Solutions for Arthritis Joint Pain: A Look at the Latest Treatments

Arthritis is a debilitating condition affecting millions of people worldwide. It leads to chronic pain, swelling, stiffness, and limited mobility in the joints, making simple activities like walking, climbing stairs, or even grasping objects difficult. Although arthritis is typically thought of as an age-related disease, it can affect people of all ages and lifestyles. As the prevalence of arthritis continues to rise, so does the demand for effective treatments that can not only relieve pain but also slow down disease progression and improve quality of life.

In recent years, advances in medicine, technology, and alternative therapies have brought forward a range of innovative solutions for managing arthritis joint pain treatment. From cutting-edge biologics and regenerative medicine to the use of advanced diagnostic tools and personalized treatments, the landscape of arthritis management has evolved significantly. This blog post explores the latest treatments for arthritis joint pain, highlighting innovative approaches that can provide relief, improve function, and help those affected by arthritis lead more fulfilling lives.

Understanding Arthritis and Its Impact

Arthritis is not a single disease but a term used to describe a range of inflammatory joint conditions. The two most common forms of arthritis are osteoarthritis (OA) and rheumatoid arthritis (RA). While both conditions lead to joint damage, their causes and treatments differ.

Osteoarthritis is the most common form of arthritis and occurs when the cartilage that cushions the ends of bones wears down over time, leading to joint pain and stiffness. It is typically associated with aging or joint injury.

Rheumatoid arthritis, on the other hand, is an autoimmune condition where the body's immune system mistakenly attacks the joints, leading to inflammation, pain, and potential joint deformity.

Other forms of arthritis include psoriatic arthritis, gout, ankylosing spondylitis, and juvenile arthritis, each requiring specialized treatment approaches. Regardless of the type, arthritis is characterized by joint pain and inflammation, and the severity can vary from mild discomfort to debilitating pain and immobility.

Although there is no cure for arthritis, early diagnosis and intervention can significantly reduce symptoms and slow disease progression. In recent years, medical science has developed a variety of innovative treatments that can help people manage arthritis joint pain more effectively.

Innovative Solutions in Arthritis Joint Pain Relief

1. Biologic Drugs: Targeting the Immune System

Biologics have revolutionized the treatment of autoimmune forms of arthritis, particularly rheumatoid arthritis and psoriatic arthritis. Unlike traditional medications, biologics are designed to target specific proteins in the immune system that cause inflammation, offering more targeted and effective relief for arthritis symptoms.

How Biologics Work

Biologic drugs are made from living organisms and are designed to target specific molecules involved in the inflammatory process. These treatments have transformed the management of arthritis, offering significant pain relief, slowing disease progression, and improving joint function.

Some of the most widely used biologics for arthritis include:

Tumor Necrosis Factor (TNF) Inhibitors: These medications, including etanercept (Enbrel), adalimumab (Humira), and infliximab (Remicade), block the action of tumor necrosis factor (TNF), a protein that plays a central role in the inflammatory process in arthritis.

Interleukin (IL) Inhibitors: Medications like tocilizumab (Actemra) and sarilumab (Kevzara) target interleukins, which are signaling molecules involved in inflammation.

B-cell Depleting Agents: Rituximab (Rituxan) targets B cells, which play a role in the immune system's attack on the joints.

These biologic agents are typically administered via injection or infusion and have been shown to significantly reduce joint pain, swelling, and stiffness. They are particularly beneficial for individuals whose arthritis has not responded to traditional disease-modifying antirheumatic drugs (DMARDs).

While biologics are highly effective, they do come with potential side effects, such as increased susceptibility to infections and other immune-related issues. Therefore, it’s important to use these drugs under the guidance of a healthcare professional.

2. Regenerative Medicine: Harnessing the Body’s Healing Power

Regenerative medicine is one of the most exciting frontiers in arthritis treatment. These therapies focus on repairing or regenerating damaged tissues to restore joint function and reduce pain. Regenerative medicine approaches aim to address the root causes of arthritis by promoting tissue healing and regeneration at the cellular level.

Platelet-Rich Plasma (PRP) Therapy

Platelet-rich plasma (PRP) therapy involves the extraction of a patient’s blood, which is then processed to concentrate the platelets and growth factors. These are then injected into the affected joint. The high concentration of growth factors in PRP is believed to stimulate healing, reduce inflammation, and improve joint function.

PRP therapy has shown promising results in treating osteoarthritis, particularly in the knee, hip, and shoulder joints. It is a minimally invasive treatment that can provide relief for patients who have not responded to more conventional treatments.

Stem Cell Therapy

Stem cell therapy is another regenerative medicine treatment that holds great potential for arthritis relief. Stem cells, particularly those derived from bone marrow or adipose (fat) tissue, have the ability to differentiate into various types of cells, including cartilage cells. When injected into an arthritic joint, stem cells can potentially regenerate damaged cartilage, reduce inflammation, and improve joint function.

Although stem cell therapy is still being researched, early clinical trials have shown promising results in treating knee osteoarthritis and other joint conditions. As research continues, stem cell therapy could become a more widely available treatment for arthritis sufferers.

3. Gene Therapy: The Future of Arthritis Treatment

Gene therapy is an innovative and emerging treatment that aims to modify or replace defective genes to treat disease. In the case of arthritis, gene therapy seeks to introduce new genetic material into the body to promote the production of molecules that can reduce inflammation or repair damaged joints.

How Gene Therapy Works for Arthritis

The goal of gene therapy for arthritis is to deliver genes that encode for anti-inflammatory proteins or cartilage-repairing molecules. For example, a gene therapy treatment could deliver a gene that encodes for the production of collagen, which is a key component of cartilage. This could help slow down or even reverse joint damage in individuals with osteoarthritis or rheumatoid arthritis.

Though still in the experimental stages, gene therapy offers tremendous potential to treat arthritis more effectively and could play a major role in the future of arthritis management.

4. Advanced Joint Injections: More Effective Relief

Joint injections have long been a staple of arthritis joint pain treatment, but recent innovations have enhanced the effectiveness of these therapies.

Hyaluronic Acid Injections

Hyaluronic acid is a substance naturally found in synovial fluid, which lubricates and cushions joints. Injections of hyaluronic acid into the affected joint can help restore lubrication, reduce friction, and alleviate pain, especially in patients with osteoarthritis. These injections are particularly effective in knee osteoarthritis and can provide relief for several months.

Corticosteroid Injections

Corticosteroids are powerful anti-inflammatory medications that can be injected directly into the affected joint to quickly reduce inflammation and pain. While these injections provide significant relief, they are typically used sparingly due to potential side effects, such as cartilage damage with repeated use.

Prolotherapy

Prolotherapy involves injecting a solution, usually a sugar-based compound, into the damaged joint or surrounding tissues. The solution triggers a mild inflammatory response, promoting healing and tissue regeneration. Prolotherapy has shown promise for treating osteoarthritis, particularly in the knee and spine.

5. Non-Pharmacological Treatments: Enhancing Quality of Life

While medications and injections are crucial components of arthritis management, non-pharmacological treatments also play a vital role in improving the quality of life for those with arthritis. These treatments focus on lifestyle changes and therapies that can reduce pain, improve mobility, and promote overall well-being.

Physical Therapy

Physical therapy is a cornerstone of arthritis treatment, helping patients improve joint function, build strength, and reduce pain. Through tailored exercise programs, physical therapists can help patients improve flexibility, reduce stiffness, and maintain mobility.

Occupational Therapy

Occupational therapists assist patients in modifying their environment and teaching them techniques to perform daily tasks more easily and with less pain. This can include using assistive devices such as braces, splints, or ergonomic tools.

Mind-Body Therapies

Chronic pain can take a significant emotional toll on individuals with arthritis. Mind-body therapies such as yoga, tai chi, meditation, and cognitive behavioral therapy (CBT) can help reduce stress, improve mental health, and manage the emotional aspects of living with chronic pain. These therapies can also promote relaxation and reduce muscle tension, which may help alleviate arthritis-related discomfort.

Conclusion:

Arthritis joint pain treatment is a complex condition that affects millions of people worldwide, but thanks to groundbreaking advances in medicine and technology, the future of arthritis treatment is brighter than ever. From biologics that target the immune system to regenerative therapies that harness the body’s own healing power, patients now have access to innovative treatments that can significantly reduce pain, slow disease progression, and improve quality of life.

As research continues to evolve, new treatments and therapies will undoubtedly emerge, providing even more options for arthritis patients. However, it is important to remember that there is no one-size-fits-all solution. Every person’s arthritis is unique, and a combination of treatments may be necessary to achieve the best results.

By staying informed about the latest advancements and working closely with healthcare professionals, individuals with arthritis can take an active role in managing their condition and enjoy a higher quality of life.

Let's Connected Name: Orthopedic Specialists Address: 360 W Butterfield Rd # 160, Elmhurst, IL 60126, United States Phone No: +1 6307829600 Map: https://maps.app.goo.gl/zVGiG6Qcvryrokkp8

[patientexperts12]

Best Rheumatoid Arthritis Treatment Options Available in Dubai: A Comprehensive Guide

Rheumatoid arthritis (RA) is a chronic inflammatory illness that affects more than just the joints. It can also harm other organs, including the skin, eyes, lungs, hearts, and blood vessels. If you are looking for the Best Rheumatoid Arthritis Treatment in Dubai, Patientexperts.co can help you connect with the right rheumatology doctors in Dubai. 

RA is an autoimmune condition, which means that the body's immune system attacks its tissues. Joint injury frequently affects both sides of the body. This is one distinction between RA and Osteoarthritis.

Symptoms

Joint discomfort and inflammation occur during flares, also known as exacerbations. They also occur during remission, which is when all symptoms disappear. Although rheumatoid arthritis affects other body systems (as previously stated), the following symptoms and signs are included: 

Joint swelling 

Joint discomfort

Joint stiffness 

Deformities or lack of joint function 

Fatigue

Morning stiffness

Joint stiffness 

Joint discomfort

Minor joint oedema

Fever 

Numbness and tingling

Reduced range of motion

According to Rheumatology Specialist doctors in Dubai, several different symptoms can be felt during the early stages: 

Dry mouth

Weight loss

General weakness

Dry, itchy, or irritated eyes 

Problems sleeping 

Eye discharge 

Chest pain while breathing

Loss of appetite 

Treatment alternatives 

Although there is no cure for RA, many clinical studies show that remission is achievable if symptoms are identified early and treated with pharmaceuticals known as disease-modifying antirheumatic drugs (DMARDs). 

Medications 

Medications are prescribed based on the specific type of RA, the severity, and the duration of your symptoms. According to rheumatologists in Dubai, the following options exist: 

NSAIDs: These are nonsteroidal anti-inflammatory medications. They aid in relieving pain and reduce inflammation. Over-the-counter NSAIDs include ibuprofen and naproxen sodium. Other stronger choices will be accessible with a prescription. Side effects include stomach infections and heart and renal difficulties. 

Steroids: Corticosteroids are typically used by doctors to swiftly ease pain. Corticosteroid medicines, such as prednisone, help to reduce inflammation and joint degeneration. These are administered to progressively lower the dosage over time. Side effects include bone weakening, weight gain, and/or diabetes. 

Conventional DMARDs: They assist in halting the progression of RA and prevent irreparable damage to the joints and other tissues. Common DMARDs include methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine. Common adverse effects, if occurring, include life damage and serious lung infections. 

Biological agents: This is a relatively new family of DMARDs that is typically used in conjunction with conventional DMARDs. Abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, sarilumab, and tocilizumab are all examples of biological response modifiers. Even they pose a danger of illness. 

Therapy 

Doctors at the leading hospitals in Dubai may send you to a physiotherapist, who will teach you basic and effective exercises to keep your joints flexible. He may also propose alternative and easier ways to complete fundamental chores. 

You may also be recommended assistive gadgets geared at reducing stress and joint pain, making it easier for you to do tasks. 

Surgery

Any rheumatologist in Dubai will agree that surgery is and should always be the last resort if drugs and other alternatives have failed to provide relief. Any type of surgery involves the danger of bleeding, infection, and pain. Surgery can restore joint functionality while also reducing discomfort. The various alternatives at the leading hospitals in Dubai include: 

Synovectomy: Procedure to remove the joint's inflammatory lining (synovium). 

Tendon repairs: This heals the tendons surrounding the joint that has loosened or ruptured due to inflammation. 

Joint fusion: If joint replacement is not an option, fusion may be used to stabilise or realign a joint. 

Total joint replacement: The injured joint is removed and replaced with a metal and plastic prosthesis. 

Synovectomy: Procedure to remove the joint's inflammatory lining (synovium). 

Tendon repairs: This heals the tendons surrounding the joint that has loosened or ruptured due to inflammation. 

Joint fusion. If joint replacement is not an option, fusion may be used to stabilise or realign a joint. 

Total joint replacement: The injured joint is removed and replaced with a metal and plastic prosthesis. 

Conclusion

If you are looking for the Best Rheumatoid Arthritis Treatment in Dubai, Patientexperts.co can help you connect with the right doctors. Contact us today to know more! 

[drpriya]

Several medications are commonly used for arthritis treatment, depending on the type of arthritis and its severity.

Some of the most commonly prescribed medications include:

Nonsteroidal anti-inflammatory drugs (NSAIDs): These drugs, such as ibuprofen, naproxen, and aspirin, help reduce pain and inflammation associated with arthritis.

Disease-modifying antirheumatic drugs (DMARDs): DMARDs, such as methotrexate, sulfasalazine, and hydroxychloroquine, are used to slow down the progression of inflammatory arthritis by suppressing the immune system's abnormal response.

Biologic response modifiers (biologics): Biologics, including TNF inhibitors (e.g., adalimumab, etanercept, infliximab), interleukin inhibitors (e.g., tocilizumab, sarilumab), and other targeted therapies, target specific molecules involved in the inflammatory process of arthritis.

Corticosteroids: These powerful anti-inflammatory medications, such as prednisone and cortisone, are used to quickly reduce inflammation and alleviate symptoms during arthritis flares. They are often used short-term due to potential long-term side effects.

Analgesics: Pain relievers, such as acetaminophen (paracetamol), tramadol, and opioid medications, may be used to manage arthritis pain, particularly when NSAIDs are not suitable or insufficient.

Topical treatments: Topical NSAIDs, capsaicin creams, and topical corticosteroids can be applied directly to the skin over affected joints to relieve pain and inflammation.

Janus kinase (JAK) inhibitors: These newer medications, such as tofacitinib and baricitinib, target specific enzymes involved in the inflammatory process and are used to treat certain types of inflammatory arthritis.

Immunomodulators: Drugs like azathioprine, cyclosporine, and mycophenolate mofetil are sometimes used to suppress the immune system and reduce inflammation in certain forms of arthritis.

Individuals with arthritis work closely with their healthcare providers to determine the most appropriate medication regimen based on their specific diagnosis, symptoms, medical history, and other factors.

Determining the effectiveness of biosimilars compared to other medications depends on various factors, including the specific condition being treated, individual patient characteristics, and clinical trial data.

Here are some considerations:

Clinical efficacy: Biosimilars are required to demonstrate similar efficacy to the reference biologic drug through rigorous clinical trials. Studies have shown that biosimilars are generally as effective as their reference products in treating conditions such as rheumatoid arthritis, inflammatory bowel disease, and certain types of cancer.

Safety: Biosimilars undergo extensive safety evaluations to ensure they have a similar safety profile to the reference product. Adverse events associated with biosimilars are typically consistent with those of the reference biologic drug.

Cost-effectiveness: Biosimilars are often priced lower than their reference products, leading to potential cost savings for healthcare systems, insurers, and patients. This increased affordability can improve access to biologic therapies for patients who may otherwise face financial barriers.

Patient preference and tolerability: Some patients may have individual preferences or better tolerability with certain medications, whether they are biosimilars or reference biologics. Factors such as route of administration, frequency of dosing, and side effect profiles can influence treatment choices.

Ultimately, the choice between biosimilars and other medications depends on a thorough evaluation of clinical evidence, cost considerations, patient preferences, and healthcare provider recommendations.

In many cases, biosimilars offer a safe and effective alternative to reference biologic drugs, providing patients with additional treatment options and potentially reducing healthcare costs. However, individualized treatment decisions should always be made in consultation with a healthcare professional.

Get the best treatments for various diseases and full body health checkup at the best hospitals in India.

[researchupdates]

Sarilumab Market Analysis & Forecast Report 2021-2028 with Estimated Key Players- Regeneron Pharma, Sanofi

Global Sarilumab Market Synopsis:

The exclusive research report on the Global Sarilumab Market 2021-2028 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Sarilumab Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.

The Global Sarilumab Market is expected to grow at a CAGR of 7.90% in the forecast period of 2021 to 2028.

Available Exclusive Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sarilumab-market .

According to the market research, Sarilumab is a monoclonal antibody which acts by blocking Interleukin-6. This medication is used for the treatment of rheumatoid arthritis and helps by reducing pain and swelling. It is also used to treat community-acquired pneumonia and others.

Some of the most important key factors driving the growth of the Global Sarilumab Market are increasing geriatric population, rise in the prevalence of rheumatoid arthritis, growing concentration of major pharmaceutical companies. Growing government initiatives and rising awareness.

The major players covered in the Global Sarilumab Market report are Regeneron Pharmaceuticals Inc. and Sanofi, among other domestic and global players.  

Regionally, North America dominates the Sarilumab Market due to the presence of major key players, continuous technological development, well-developed healthcare sector, increasing prevalence of diseases, and increasing awareness towards health in this region. Global Sarilumab Market in the APAC and Europe is expected to grow during the forecast period due to the increasing R&D activities, rising investment in the healthcare sector, increasing demand for the treatment, and increasing geriatric population.

Purchase this report online with 350 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Sarilumab Market Report 2021” @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-sarilumab-market .

[bidhuan]

2 Obat Arthritis Bisa Kurangi Resiko Kematian Pasien COVID-19

2 Obat Arthritis Bisa Kurangi Resiko Kematian Pasien COVID-19

Majalah Farmasetika – Penelitian terbaru temukan dua obat yang digunakan untuk mengobati rheumatoid arthritis dapat mengurangi rawat inap rumah sakit COVID-19 sebanyak 10 hari, dan menyelamatkan nyawa satu dari 12 pasien perawatan intensif dengan virus corona. Salah satu pengobatan, tocilizumab, dapat mengurangi risiko kematian relatif sebesar 24% bila diberikan kepada pasien dalam waktu 24 jam…

[acuguy]

CoVID-19 and Drugs Used

At the moment there is no medication that is specific for treating COVID-19 but yes, there are talks of drugs that have been repurpose for treating SARS-CoV2, the virus that causes COVID-19. Which are those drugs and how they work? Do they promise any hope for stopping this virus?

WHO has started a trial program with the purpose to analyze different medications and their effect on the virus. The medications that made the cut are:

Remdesivir - the medication was mainly created to treat Ebola, but it has been noticed in labs that it can treat SARS and MERS, two coronavirus that behave similar to COVID-19. This medication works by inhibiting the enzyme RNA-Polymerase. With this enzyme out, the virus can’t replicate its RNA. It has been noticed that it’s effectiveness is during mild to moderate signs and symptoms of COVID-19.

 Chloroquine and hydroxychloroquine - an antimalarial medication that reduces acidity in an endosome. An endosome is a vesicle that our cells use as transportation. Chloroquine and hydroxychloroquine prevents COVID-19 from using this method. There are two problems to this medication: first COVID-19 uses ACE-2 receptors as a way of propagation and not endosomes. Second, the dose to make it work is 600 to 800 mg for 10 days. The safe dose is 5 mg/kg/day, it is unknown if this high dose for 10 days causes problem. The French Doctor Didier Raoult, MD, PhD claims that hydroxychloroquine plus the antibiotic azytromicin cures COVID-19 and drops the viral load in a short period of time. Hydroxychloroquine is less toxic than chloroquine. This medication is used for LUPUS, Rheumatoid arthritis and other autoimmune disorders.

Ritonavir/Lopinavir - known in USA as Kaletra, this HIV medication prevents proteins from being transformed into smaller units that later will be use for translation and replication of the virus. It has been noticed that this medication works better at the beginning stage of the virus.

 Ritonavir/Lopinavir/Interferon Beta - this combination seems more promising as long as there is no severe symptoms of inflammation. In that case, interferon could cause more damage than help. The interferon beta is produced by Cuba.

ACEI’s and Angiotensin Converting Enzyme Receptors Blockers (ARB) - Angiotensin Converting Enzyme Inhibitors are meds for high blood pressure, kidney problems, or coronary problems. This medication is not being used by WHO in the trial but it is worth mentioning. SARSCOV-2 uses ACE2 to enter the body and it was hypothesized that blocking this receptors would help stop the virus but it has been noticed that the body increases the production of ACE receptors facilitating the propagation of the virus. If you or anyone you know uses any of the medications, please do not stop taking them. Please, self-quarantine and observe all the recommendations such as using a face mask, and keeping a 1.5 meter (6 feet) distance.

Tocilizumab or Sarilumab - It is not being used in the trial by WHO but, again, it is worth mentioning. This medication is an immunosuppressant and its purpose is to reduce IL-6 (interleukin 6) and prevent a cytokine storm in some patients. Some patients’ immune system go crazy before SARSCOV-2 and can cause more harm than help, therefore the medication.

Ivermectin - is an antiparasitic medicine that seems to clear the virus within 48 hours. Studies were done in vitro. Is not on the WHO list of meds in trial.

Favipiravir - an antiviral medication with a wide spectrum of action against different virus such as influenza, and ebola. This medication inhibits the replication of a virus and lowers viral load. China is sending it to Turkey while Japan has entered in talks with USA and other countries. This medicine is not part of WHO's trial.

In summary, there is no drug available. It takes time to develop and test one. At the moment, the medical community is repurposing some drugs and reporting to WHO in order to determine a best course of action. Therefore, the best action is, isolate, wash your hands, use a face mask, and keep a distance of 6 feet (1.5 meters). 

REFERENCES:

WHO launches global megatrial of the four most promising coronavirus treatments.  By Kai Kupferschmidt, Jon Cohen. AAAS. Science. March 22, 2020. Accessed April 4th, 2020.

Chronic use of heart disease medications may increase the risk of severe COVID-19. By Hannah Balfour. Drug Target Review. 24 March 2020. Accessed April 4th, 2020.

Treatments for COVID-19: Drugs being tested against the coronavirus. Live Science. 

Hydroxychloroquine: Possible COVID Drug Can Be Toxic to Retinas. Brianne N Hobbs,OD; Kalia M Osmotherly, OD. 2 April 2020. Accessed April 4th, 2020. 

‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19. By Elizabeth Cooney. 26 March 2020. Accessed April 4th, 2020.

Coronavirus: What is Ivermectin and how it works. AS.COM. 4 April 2020.

Japan Is Racing to Test a Drug to Treat Covid-19. By Joshua Hunt. Wired.com 4 April 2020.

CoVID-19: More Hydroxychloroquine data from France, more questions. Veronique Duqueroy. Hospitalist. 1 April 2020.

Chloroquine and Hydroxychloroquine as available weapons to fight COVID-19. International Journal of Antimicrobial Agents.

[somuchtostudysolittletime]

Oddly niche pharmacist things:

Today I learnt tocilizumab is licenced for covid

I can’t tell if I’m shocked it’s ALREADY licenced or shocked that they didn’t licence it sooner. Either way I’m shocked I only learnt about it today.

[pharmatimesng]

Two more life-saving Covid drugs discovered

Two more life-saving Covid drugs discovered

Two more life-saving drugs have been found that can cut deaths by a quarter in patients who are sickest with Covid. The anti-inflammatory medications, given via a drip, save an extra life for every 12 treated, say researchers who have carried out a trial in NHS intensive care units. Supplies are already available across the UK so they can be used immediately to save hundreds of lives, say…

[murraypdavid]

Good News: Tocilizumab (Actemra) & Sarilumab (Kevzara) for COVID 19

[ebolanyt]

Arthritis Drug Did Not Help Seriously Ill Covid Patients, Early Data Shows

By Gina Kolata The drug, sarilumab, sold as Kevzara, didn’t show benefits to patients who were hospitalized but not on ventilators. The study will continue with critically ill patients. Published: April 27, 2020 at 01:55PM from NYT Health https://ift.tt/2W8RAts via IFTTT

[bidhuan]

Mengenal Sarilumab sebagai Obat COVID-19, Analog dari Tocilizumab

Mengenal Sarilumab sebagai Obat COVID-19, Analog dari Tocilizumab

Majalah Farmasetika – Covid-19 muncul pertama kali di Wuhan, Cina dan menyebar dengan cepat hampir ke seluruh negara di dunia. Pemakaian Sarilumab sebagai obat Covid-19 muncul karena pemakaian tocilizumab, antibody monoclonal, yang merupakan inhibitor interleukin-6 untuk mengobati pneumonia Covid-19.

Namun, peningkatan pemakaian tocilizumab ini menyebabkan habisnya stock tocilizumab, sehingga…

[madeinhistory-archived]

yo good news

1) i actually have muse! im actually going to write and talk to people  like a fucking  person for once rip 2) my CRP has gone down a lot. My SED rate and general inflammation level is high but it’s a good sign. he gave me sarilumab on top of my weekly 25 mg of methotrexate so we’ll see how it goes